Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

Kuros Biosciences AG / Key word(s): Conference Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference 01.02.2024 / 07:00 CET/CEST Schlieren (Zurich), Switzerland, February 1, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it will present at the CG 2024 Musculoskeletal Conference, to be held in San Francisco on February 12, 2024. At the conference, management will discuss its novel MagnetOs portfolio of products and its application to spinal fusion.

Presentation details are as follows:

Presenter:  Chris Fair, Chief Executive Officer of Kuros Biosciences
Presentation time: 10:00 am – 10:25 am EDT
Location: Colonial Room

Additional executive leadership team members in attendance: Daniel Geiger, Chief Financial Officer and Joost de Bruijn, Executive Director and President of Innovation and Strategy

A replay of the presentation will be available for 90 days following the conference.  You may access the replay directly here, or via the Reports & Corporate Governance section of Kuros’ website within “Reports & Presentations”.

Kuros management will also be available for one on ones during the conference.  Please contact your CG representative should you have interest in setting up a meeting.

About the CG Musculoskeletal Conference 2024
The CG (“Canaccord Genuity”) Musculoskeletal Conference is a one-day event to explore the current state of orthopedics, robotic surgery, imaging/enabling technologies, biologics, and regenerative medicine companies.

About MagnetOs
MagnetOs is a bone graft like no other: thanks to its NeedleGrip^TM surface technology, it grows bone even in soft tissues.* This surface technology provides traction for our body’s vitally important ‘pro-healing' immune cells (M2 macrophages).^†‡1,2 This in turn, unlocks previously untapped potential to stimulate stem cells - and form new bone throughout the graft.^†§3-6  The growing body of science behind NeedleGripTM is called osteoimmunology. But for surgeons and their patients it means one thing: a more predictable fusion.^†¶5,6